Similar to other biotechs or growth pharma as Allergen (AGN) calls itself, the stock trades at lows far below the highs over a year ago. The CEO took the blame for the large Q3 earnings miss and predicted top-tier growth next year. https://twitter.com/brianfires/status/793812919490183168/photo/1!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+"://platform.twitter.com/widgets.js";fjs.parentNode.insertBefore(js,fjs);}}(document,"script","twitter-wjs");The company is backing this thesis by committing a total of $15 billion to share buybacks. The story appears very compelling as the election on Tuesday should end some of the extreme pressure on the sector. Anybody buying the dip here?Disclosure: No position